Non-communicable diseases and patients’ metabolic health: a public health perspective

Authors

DOI:

https://doi.org/10.32782/2786-7684/2025-2-25

Keywords:

metabolic dysfunction-associated steatotic liver disease, metabolic health, non-communicable diseases, public health, steatosis, screening, ultrasound steatometry

Abstract

Introduction. Since the onset of the full-scale war in Ukraine, the issue of non-communicable diseases – many of which are associated with metabolic disorders – has become significantly more acute. Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common non-communicable diseases, exacerbating comorbidities, accelerating the onset of complications, and considerably reducing patients' quality of life.Objective. To explore credible sources for potential links between non-communicable diseases and metabolic disorders, and to assess MASLD in the context of public health.Materials and Methods. A literature search was conducted using PubMed and Medline databases, along with an analysis of information from the official website of the Public Health Center of the Ministry of Health of Ukraine.Results and Discussion. The article discusses the current state of metabolic-associated non-communicable diseases, with a primary focus on MASLD, which has emerged as a major public health and healthcare system challenge. MASLD has taken on the features of a non- infectious pandemic, affecting 30–40% of the global population. The disease carries not only medical but also socio-economic implications.The article describes the epidemiology of MASLD and its association with overweight and obesity, type 2 diabetes, arterial hypertension, and increased cancer risk. The importance of screening for steatosis is emphasized, with early therapeutic intervention aimed at reducing adverse health outcomes.Conclusions. An interdisciplinary approach to the medical and social challenge of MASLD – the most prevalent NCD worldwide – should be comprehensive and centered on understanding the comorbidity paradigm and its impact on population health. A crucial step is the development and implementation of a holistic community-level program with clear guidelines for screening, early diagnosis, treatment, and complication prevention. Only a well-defined strategy to combat MASLD can yield success and improve the overall health profile of Ukrainians.

References

Ukraine: Public Health Situation Analysis (PHSA) – Long-form (Last Update: July 2022) Available from: https://portal.phc.org.ua/media/who_file_previews/PHSA_Ukraine_July2022_final_ENG-UKR-090922.pdf [in Ukranian]

United Nations Ukraine, STEPS survey reveals high prevalence of noncommunicable disease risk factors in Ukraine, 18 November 2020. Available from: https://ukraine.un.org/en/101169-steps-survey-reveals-high-prevalence-noncommunicable-disease-risk-factors-ukraine

Vebsait Tsentru hromadskoho zdorovia MOZ Ukrainy. Available from: https://apps.phc.org.ua/learner-dashboard/

Dumcheva A. Tackling noncommunicable diseases in Ukraine 2015–2019. Copenhagen: WHO Regional Office for Europe; 2020. Available from: https://www.euro.who.int/__data/assets/pdf_file/0009/425763/Tackling-noncommunicable-diseases-in-Ukraine-2015-2019.pdf

EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Journal of Hepatology [Internet]. 2024 Sep;(81):492–542. Available from: https://www.journal-of-hepatology.eu/article/S0168-8278(24)00329-5/fulltext

Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology (Baltimore, Md) [Internet] 2023;77(4):1335–47. Available from: https://pubmed.ncbi.nlm.nih.gov/36626630/

Dynnyk OB. Zhyr Vashoho tila. Zhyr Vashoi pechinky. Proste podolannia [Your Body Fat. Your Liver Fat. Easy Overcoming]. Kyiv; 2023. 82 s. [in Ukrainian]

Quek J, Chan KE, Wong ZY. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol [Internet] 2023;8(1):20–30. Available from: https://doi.org/10.1016/S2468-1253(22)00317-X

Le MH, Le DM, Baez TC. Global incidence of non-alcoholic fatty liver disease: a systematic review and meta-analysis of 63 studies and 1,201, 807 persons. J Hepatol [Internet] 2023;79(2):287–95. Available from: https://doi.org/10.1016/j.jhep.2023.03.040

Golabi P, Paik JM, Kumar A. Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States. Metabolism. 2023;146:155642. Available from: https://doi.org/10.1016/j.metabol.2023.155642

Ajmera V, Cepin S, Tesfai K. A prospective study on the prevalence of NAFLD, dvanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J Hepatol [Internet] 2023;78(3):471–78. Available from: https://doi.org/10.1016/j.jhep.2022.11.010

International Diabetes Federation, IFD Statement on the ongoing situation in Ukraine, 21 March 2022. Available from: https://idf.org/news/idf-statement-on-the-ongoing-situation-in-ukraine/

En Li Cho E, Ang CZ, Quek J. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut. 2023;72(11):2138–48. Available from: https://doi.org/10.1136/gutjnl-2023-330110

Simon TG, Roelstraete B, Sharma R. Cancer risk in patients with biopsy-confirmed nonalcoholic fatty liver disease: a population-based cohort study. Hepatology (Baltimore, Md). 2021;74(5):2410–23. Available from: https://doi.org/10.1002/hep.31845

Zhao L, Zhang X, Coday M, et al. Sugar-sweetened and artificially sweetened beverages and risk of liver cancer and chronic liver disease mortality. JAMA. 2023;330(6):537–46. Available from: https://doi.org/10.1001/jama.2023.12618

Zhang YB, Pan XF, Chen J, et al. Combined lifestyle factors, incident cancer, and cancer mortality: a systematic review and meta-analysis of prospective cohort studies. Br J Cancer. 2020;122(7):1085–93. Available from: https://doi.org/10.1038/s41416-020-0741-x

Sjöholm K, Carlsson LMS, Svensson P-A, et al. Association of bariatric surgery with cancer incidence in patients with obesity and diabetes: longterm results from the Swedish obese subjects study. Diabetes Care. 2022;45(2):444–50. Available from: https://doi.org/10.2337/dc21-1335

Published

2025-06-30

Issue

Section

PUBLIC HEALTH